693 research outputs found

    Systems approaches to drug repositioning

    Get PDF
    PhD ThesisDrug discovery has overall become less fruitful and more costly, despite vastly increased biomedical knowledge and evolving approaches to Research and Development (R&D). One complementary approach to drug discovery is that of drug repositioning which focusses on identifying novel uses for existing drugs. By focussing on existing drugs that have already reached the market, drug repositioning has the potential to both reduce the timeframe and cost of getting a disease treatment to those that need it. Many marketed examples of repositioned drugs have been found via serendipitous or rational observations, highlighting the need for more systematic methodologies. Systems approaches have the potential to enable the development of novel methods to understand the action of therapeutic compounds, but require an integrative approach to biological data. Integrated networks can facilitate systems-level analyses by combining multiple sources of evidence to provide a rich description of drugs, their targets and their interactions. Classically, such networks can be mined manually where a skilled person can identify portions of the graph that are indicative of relationships between drugs and highlight possible repositioning opportunities. However, this approach is not scalable. Automated procedures are required to mine integrated networks systematically for these subgraphs and bring them to the attention of the user. The aim of this project was the development of novel computational methods to identify new therapeutic uses for existing drugs (with particular focus on active small molecules) using data integration. A framework for integrating disparate data relevant to drug repositioning, Drug Repositioning Network Integration Framework (DReNInF) was developed as part of this work. This framework includes a high-level ontology, Drug Repositioning Network Integration Ontology (DReNInO), to aid integration and subsequent mining; a suite of parsers; and a generic semantic graph integration platform. This framework enables the production of integrated networks maintaining strict semantics that are important in, but not exclusive to, drug repositioning. The DReNInF is then used to create Drug Repositioning Network Integration (DReNIn), a semantically-rich Resource Description Framework (RDF) dataset. A Web-based front end was developed, which includes a SPARQL Protocol and RDF Query Language (SPARQL) endpoint for querying this dataset. To automate the mining of drug repositioning datasets, a formal framework for the definition of semantic subgraphs was established and a method for Drug Repositioning Semantic Mining (DReSMin) was developed. DReSMin is an algorithm for mining semantically-rich networks for occurrences of a given semantic subgraph. This algorithm allows instances of complex semantic subgraphs that contain data about putative drug repositioning opportunities to be identified in a computationally tractable fashion, scaling close to linearly with network data. The ability of DReSMin to identify novel Drug-Target (D-T) associations was investigated. 9,643,061 putative D-T interactions were identified and ranked, with a strong correlation between highly scored associations and those supported by literature observed. The 20 top ranked associations were analysed in more detail with 14 found to be novel and six found to be supported by the literature. It was also shown that this approach better prioritises known D-T interactions, than other state-of-the-art methodologies. The ability of DReSMin to identify novel Drug-Disease (Dr-D) indications was also investigated. As target-based approaches are utilised heavily in the field of drug discovery, it is necessary to have a systematic method to rank Gene-Disease (G-D) associations. Although methods already exist to collect, integrate and score these associations, these scores are often not a reliable re flection of expert knowledge. Therefore, an integrated data-driven approach to drug repositioning was developed using a Bayesian statistics approach and applied to rank 309,885 G-D associations using existing knowledge. Ranked associations were then integrated with other biological data to produce a semantically-rich drug discovery network. Using this network it was shown that diseases of the central nervous system (CNS) provide an area of interest. The network was then systematically mined for semantic subgraphs that capture novel Dr-D relations. 275,934 Dr-D associations were identified and ranked, with those more likely to be side-effects filtered. Work presented here includes novel tools and algorithms to enable research within the field of drug repositioning. DReNIn, for example, includes data that previous comparable datasets relevant to drug repositioning have neglected, such as clinical trial data and drug indications. Furthermore, the dataset may be easily extended using DReNInF to include future data as and when it becomes available, such as G-D association directionality (i.e. is the mutation a loss-of-function or gain-of-function). Unlike other algorithms and approaches developed for drug repositioning, DReSMin can be used to infer any types of associations captured in the target semantic network. Moreover, the approaches presented here should be more generically applicable to other fields that require algorithms for the integration and mining of semantically rich networks.European and Physical Sciences Research Council (EPSRC) and GS

    RESKO: Repositioning drugs by using side effects and knowledge from ontologies

    Get PDF
    The objective of drug repositioning is to apply existing drugs to different diseases or medical conditions than the original target, and thus alleviate to a certain extent the time and cost expended in drug development. Our system RESKO, REpositioning drugs using Side Effects and Knowledge from Ontologies, identifies drugs with similar side-effects which are potential candidates for use elsewhere, the supposition is that similar side-effects may be caused by drugs targeting similar proteins and pathways. RESKO, integrates drug chemical data, protein interaction and ontological knowledge. The novel aspects of our system include a high level of biological knowledge through the use of pathway and biological ontology integration. This provides a explanation facility lacking in most of the existing methods and improves the repositioning process. We evaluate the shared side effects from the eight conventional Alzheimer drugs, from which sixty-seven candidate drugs based on a side-effect commonality were identified. The top 25 drugs on the list were further investigated in depth for their suitability to be repositioned, the literature revealed that many of the candidate drugs appear to have been trialed for Alzheimer's disease. Thus verifying the accuracy of our system, we also compare our technique with several competing systems found in the literature

    Drug repurposing: cost effectiveness and impact on emerging and neglected diseases

    Get PDF
    Historically, pressure on nature brought about by ever-increasing human pollution and technological advancement culminate in emergence and re- emergence of infectious and non-infectious diseases; necessitating medications and drug discovery and development. The emergence of resistantmicroorganisms and the emergence of new infections disease conditions necessitate the production of entirely new drugs or modification of the existing ones to increase their efficacy. The development of novel medications is a very long and expensive process. There is a significant decrease observed in the number of new drugs approved for clinical use in recent years showing inconsistency in the face of scientific advances and research and development investment. Regardless of high investment and enormous contributions, very few molecules showed promising results. However, finding novel indications for existing drugs can be a useful method of reducing the developmental cycle of drugs. Repositioning (also called repurposing) has been described as the practice of developing new therapeutic uses for drugs, abandoned or drugs in development process, other than the initially intended or approved uses, except for the circumstances in which the novel use is comparable to the original indication with dissimilar pharmacological targets. This review aimed at looking into some of the available methods in drug repurposing. Key words: Drug discovery; Drug repurposing; Machine learning; Neglected Tropical diseases; Orphan drug

    The value of semantics in biomedical knowledge graphs

    Get PDF
    Knowledge graphs use a graph-based data model to represent knowledge of the real world. They consist of nodes, which represent entities of interest such as diseases or proteins, and edges, which represent potentially different relations between these entities. Semantic properties can be attached to these nodes and edges, indicating the classes of entities they represent (e.g. gene, disease), the predicates that indicate the types of relationships between the nodes (e.g. stimulates, treats), and provenance that provides references to the sources of these relationships.Modelling knowledge as a graph emphasizes the interrelationships between the entities, making knowledge graphs a useful tool for performing computational analyses for domains in which complex interactions and sequences of events exist, such as biomedicine. Semantic properties provide additional information and are assumed to benefit such computational analyses but the added value of these properties has not yet been extensively investigated.This thesis therefore develops and compares computational methods that use these properties, and applies them to biomedical tasks. These are: biomarker identification, drug repurposing, drug efficacy screening, identifying disease trajectories, and identifying genes targeted by disease-associated SNPs located on the non-coding part of the genome.In general, we find that methods which use concept classes, predicates, or provenance improves achieve a superior performance over methods that do not use them. We thereby demonstrate the added value of these semantic properties for computational analyses performed on biomedical knowledge graphs.<br/

    DDR: efficient computational method to predict drug-target interactions using graph mining and machine learning approaches.

    Get PDF
    Motivation: Finding computationally drug-target interactions (DTIs) is a convenient strategy to identify new DTIs at low cost with reasonable accuracy. However, the current DTI prediction methods suffer the high false positive prediction rate. Results: We developed DDR, a novel method that improves the DTI prediction accuracy. DDR is based on the use of a heterogeneous graph that contains known DTIs with multiple similarities between drugs and multiple similarities between target proteins. DDR applies non-linear similarity fusion method to combine different similarities. Before fusion, DDR performs a pre-processing step where a subset of similarities is selected in a heuristic process to obtain an optimized combination of similarities. Then, DDR applies a random forest model using different graph-based features extracted from the DTI heterogeneous graph. Using 5-repeats of 10-fold cross-validation, three testing setups, and the weighted average of area under the precision-recall curve (AUPR) scores, we show that DDR significantly reduces the AUPR score error relative to the next best start-of-the-art method for predicting DTIs by 34% when the drugs are new, by 23% when targets are new and by 34% when the drugs and the targets are known but not all DTIs between them are not known. Using independent sources of evidence, we verify as correct 22 out of the top 25 DDR novel predictions. This suggests that DDR can be used as an efficient method to identify correct DTIs. Availability and implementation: The data and code are provided at https://bitbucket.org/RSO24/ddr/. Contact: [email protected]. Supplementary information: Supplementary data are available at Bioinformatics online

    Finding disease similarity based on implicit semantic similarity

    Get PDF
    AbstractGenomics has contributed to a growing collection of gene–function and gene–disease annotations that can be exploited by informatics to study similarity between diseases. This can yield insight into disease etiology, reveal common pathophysiology and/or suggest treatment that can be appropriated from one disease to another. Estimating disease similarity solely on the basis of shared genes can be misleading as variable combinations of genes may be associated with similar diseases, especially for complex diseases. This deficiency can be potentially overcome by looking for common biological processes rather than only explicit gene matches between diseases. The use of semantic similarity between biological processes to estimate disease similarity could enhance the identification and characterization of disease similarity. We present functions to measure similarity between terms in an ontology, and between entities annotated with terms drawn from the ontology, based on both co-occurrence and information content. The similarity measure is shown to outperform other measures used to detect similarity. A manually curated dataset with known disease similarities was used as a benchmark to compare the estimation of disease similarity based on gene-based and Gene Ontology (GO) process-based comparisons. The detection of disease similarity based on semantic similarity between GO Processes (Recall=55%, Precision=60%) performed better than using exact matches between GO Processes (Recall=29%, Precision=58%) or gene overlap (Recall=88% and Precision=16%). The GO-Process based disease similarity scores on an external test set show statistically significant Pearson correlation (0.73) with numeric scores provided by medical residents. GO-Processes associated with similar diseases were found to be significantly regulated in gene expression microarray datasets of related diseases
    • …
    corecore